Cooperative Agreement UG3DK142192
Award Date
1/1/25
Completion Date
12/31/26
Dollars Obligated
$1.2M
Federal Grant Program
93.847
Assistance Type
Cooperative Agreement
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the development of therapeutic interventions for Type 1...
This federal Cooperative Agreement award, with a total funding amount of $1,207,770.00 and an award date of January 1, 2025, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the role of genetically-controlled thymic epithelial cell (TEC) and hematopoietic stem cell (HSC) abnormalities in driving the development...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,232,846 to the Scripps Research Institute to study the mechanisms of initiation and progression of beta cell death in type 1 diabetes. The key objectives are to build a histocompatible vascularized micro-organ platform that can integrate patient-derived immune cells to...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,201,988 to Yale University to develop advanced pancreatic-immune organoid models for studying type 1 diabetes (T1D) subtypes and therapeutic responses. The goal is to identify B cell intrinsic features that determine T1D progression and responses to therapies. In Phase 1, the...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on enhancing the metabolic maturity of human pluripotent stem cell-derived islet organoids for improved transplantation outcomes in type 1 diabetes. The $681,562 award, granted on July 21, 2025, will support research at the University of Michigan to investigate pharmacological and 3D...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $3,067,833 Cooperative Agreement under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Brigham & Women's Hospital Inc. in Boston, MA. The award aims to discover and therapeutically target non-coding RNAs (ncRNAs) involved in accelerated atherosclerosis associated with Type 1 and Type 2 diabetes. The project will: 1) identify and prioritize ncRNA expression in human...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $823,473 Cooperative Agreement under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation (Massachusetts General Hospital) to study longitudinal omics-based trajectories of type 2 diabetes subtypes. The five-year project aims to use multi-omic data to refine definitions of prediabetes and type 2 diabetes, describe associations between...
This federal Project Grant award of $444,867.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the UPR transducer XBP1 in pancreatic beta cell survival and function under metabolic stress. The research will use a novel mouse model to elucidate the pathological role of XBP1s in beta cell integrity under metabolic stress, in order to...
This Project Grant award of $199,258 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to The Leland Stanford Junior University will fund research to develop reduced-intensity conditioning regimens to induce sustained mixed hematopoietic chimerism and tolerance for islet cell transplantation in type 1 diabetes. The research aims to 1) optimize a low-intensity conditioning protocol to reduce the radiation dose required for generating mixed chimerism, and 2)...
This $1,331,148 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research at Yale University to investigate mechanisms of islet cell compensation for B-cell mass deficiency in diabetes. The key research objectives are to: Determine the signaling mechanisms underlying B-cell compensation in a novel mouse model of B-cell replication deficiency. Elucidate the mechanisms...